TOP RATED 2025

RealRate

PHARMACEUTICAL 2025

Integrated Biopharma INC
Rank 37 of 225



PHARMACEUTICAL 2025

Integrated Biopharma INC
Rank 37 of 225

The relative strengths and weaknesses of Integrated Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Integrated Biopharma INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 182% points.The greatest weakness of Integrated Biopharma INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 195% points.

The company's Economic Capital Ratio, given in the ranking table, is 338%, being 123% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	17,875
Cost of Goods Sold	46,433
Intangible Assets	0
Liabilities, Current	6,123
Liabilities, Non-Current	846
Other Assets	6,530
Other Compr. Net Income	0
Other Expenses	156
Other Liabilities	0
Other Net Income	17
Other Revenues	50,317
Property and Equipment	1,802
Research and Development	0
Selling, General and Administrative Expense	3,633

Output Variable	Value in 1000 USD
Assets	26,207
Liabilities	6,969
Expenses	50,222
Revenues	50,317
Stockholders Equity	19,238
Net Income	112
Comprehensive Net Income	112
BaseVar	66,866
ECR before LimitedLiability	254%
Economic Capital Ratio	338%